Indeed, IL-12 was proposed for the treatment of certain cancers in which Tregs and TGF-β play a role in suppressing the activity of tumor-associated CD4+ and CD8+ T cells, but the systemic administration of soluble IL-12 in effective doses is dangerously toxic (12). Here, CD8A is linked to neoplasm.